In August, the US Food and Drug Administration (FDA) released a discussion paper outlining an enhanced systematic process for the post-market assessment of chemicals in food to identify risks to our food supply. This includes food additives, color additives, substances generally recognized as safe (GRAS), substances used in contact with food, and chemicals present as unintentional contaminants. ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Sponsored Content
Qasim Butt, MD, describes the importance of hyperkalemia management and how LOKELMA can help.
Advertisement
Latest News
The FDA has requested comments to help shape the development of a program assessing chemicals in food post-market.
Carla Nester spoke about two presentations at Kidney Week focused on potential therapies for C3 glomerulopathy.
Could adding serum C3 and C4 levels to existing predictive models for IgA nephropathy (IgAN) improve their accuracy?
Researchers compared incidence of mortality and kidney failure between patients with CKD and rare kidney diseases.
Sagar Nigwekar discussed interim data from the SEAPORT 1 trial of INZ-701 for treatment of calciphylaxis.
Jesse Goodrich and Hailey Hampson spoke about their study of the connection between PFAS, the gut, and kidney function.
Guru Reddy discussed three posters presented by Unicycive Therapeutics at ASN Kidney Week 2024, on UNI-494 and OLC.
Benefits of empagliflozin continued for a period after discontinuation but were lesser and seemed temporary.
Jonathan Barratt discussed advances in IgA nephropathy treatment with Joel Topf at ASN Kidney Week 2024.
Nephrology experts at Loma Linda University School of Medicine will host the Rare Kidney Disease Conference December 7-8.
Expert Interviews
In Print
ASN Kidney Week 2024, the future of nephrology, the relationship between CKD and osteoarthritis, and more.
Tribute to Nicoloas Madias, amino acid infusion to reduce AKI risk, felzartamab results, and more.
Conferences
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
ATC provides a forum for exchange of new scientific and clinical information relevant to transplantation.
The annual nephrology meeting organized by the European Renal Association
The National Kidney Foundation's premier educational event designed for the interprofessional kidney health team
Podcasts
Listen to the second part of the discussion of Chapter 15 of Dr. Burton Rose's book, focused on diuretics.
It's time for another NephJC draft! This time the 2024 KDIGO CKD guideline draft is on the clock!
Results of Nefecon (budesonide) for IgA nephropathy set the stage for a glomerulonephritis renaissance.
Vlado Perkovic presented results from the FLOW trial at the 61st ERA Congress, making headlines worldwide.
Expert Columns
Critical Financial Shifts Ahead: How CY 2025 ESRD PPS Changes Could Impact Small Dialysis Facilities
Sarah Tolson reviews the key financial implications of the CMS proposed rule for the ESRD Prospective Payment System.
Ajay Singh pays tribute to the late nephrologist and researcher Nicolaos Madias, MD, of Tufts Medical Center.
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW.
It is essential for nephrology practices and dialysis centers to have backup methods for processing claims.
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
Knowledge Hubs
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.